LIGAND PHARMACEUTICALS INC (LGND) — insider trading
Health Care · NASDAQ
LIGAND PHARMACEUTICALS INC (LGND) has 117 reported SEC Form 4 insider transactions in our data, including 49 open-market sales among the most recent 100 (latest 2026-10-02).
Recent Form 4 transactions
Showing the 100 most recent of 117 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion (derivative) | 340 | — | $0 | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 17 | $307.74 | $5.2K | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 235 | $307.19 | $72.2K | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 404 | $306.18 | $123.7K | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,535 | $304.52 | $467.4K | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,976 | $303.54 | $599.8K | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 833 | $302.51 | $252.0K | Form 4 |
| 2026-10-02 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion | 340 | $52.27 | $17.8K | Form 4 |
| 2026-09-22 | Zimmermann Martine | Director | Shares withheld for taxes / exercise cost | 115 | $298.50 | $34.3K | Form 4 |
| 2026-09-10 | Zimmermann Martine | Director | Open-market sale | 1,200 | $285.00 | $342.0K | Form 4 |
| 2026-09-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 400 | $288.98 | $115.6K | Form 4 |
| 2026-09-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 385 | $287.53 | $110.7K | Form 4 |
| 2026-09-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 2,115 | $286.36 | $605.6K | Form 4 |
| 2026-09-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,800 | $285.17 | $513.3K | Form 4 |
| 2026-09-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 300 | $283.99 | $85.2K | Form 4 |
| 2026-08-12 | Haas Jason | Director | Option exercise / conversion (derivative) | 6,138 | — | $0 | Form 4 |
| 2026-08-12 | Haas Jason | Director | Open-market sale | 7,138 | $292.81 | $2.09M | Form 4 |
| 2026-08-12 | Haas Jason | Director | Option exercise / conversion | 6,138 | $51.56 | $316.5K | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,074 | — | $0 | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 3,348 | — | $0 | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 16,179 | — | $0 | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,171 | — | $0 | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,869 | — | $0 | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Open-market sale | 31,641 | $292.07 | $9.24M | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 3,348 | $68.74 | $230.1K | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 7,171 | $57.22 | $410.3K | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 2,869 | $55.75 | $159.9K | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 2,074 | $70.04 | $145.3K | Form 4 |
| 2026-08-12 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 16,179 | $52.84 | $854.9K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 409 | $292.82 | $119.8K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 991 | $291.71 | $289.1K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 200 | $290.60 | $58.1K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 503 | $289.80 | $145.8K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 356 | $288.75 | $102.8K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,214 | $287.77 | $349.4K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,032 | $286.80 | $296.0K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 157 | $285.74 | $44.9K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 33 | $284.55 | $9.4K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 105 | $284.14 | $29.8K | Form 4 |
| 2026-08-03 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion | 5,000 | $52.27 | $261.4K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 600 | $317.15 | $190.3K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 900 | $315.78 | $284.2K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 100 | $314.58 | $31.5K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 700 | $313.46 | $219.4K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,081 | $312.28 | $337.6K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,119 | $311.72 | $348.8K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 104 | $310.20 | $32.3K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 396 | $308.99 | $122.4K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion | 5,000 | $52.27 | $261.4K | Form 4 |
| 2026-06-30 | Davis Todd C | Director, Officer (Chief Executive Officer) | Other acquisition or disposition | 132 | $160.71 | $21.2K | Form 4 |
| 2026-06-30 | Espinoza Octavio | Officer (Chief Financial Officer) | Other acquisition or disposition | 17 | $160.71 | $2.7K | Form 4 |
| 2026-06-30 | Reardon Andrew | Officer (CLO & Secretary) | Other acquisition or disposition | 132 | $160.71 | $21.2K | Form 4 |
| 2026-06-16 | Sabba Stephen L | Director | Option exercise / conversion (derivative) | 2,145 | — | $0 | Form 4 |
| 2026-06-16 | Sabba Stephen L | Director | Open-market sale | 2,145 | $254.00 | $544.8K | Form 4 |
| 2026-06-16 | Sabba Stephen L | Director | Option exercise / conversion | 2,145 | $66.13 | $141.8K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-12 | Haas Jason | Director | Open-market sale | 3,461 | $256.08 | $886.3K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Open-market sale | 3,000 | $255.01 | $765.0K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion | 1,000 | $51.56 | $51.6K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion | 3,000 | $51.56 | $154.7K | Form 4 |
| 2026-06-11 | Aryeh Jason | Director | Open-market sale | 4,500 | $250.00 | $1.13M | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 3,405 | $251.62 | $856.8K | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 697 | $249.53 | $173.9K | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 232 | $248.11 | $57.6K | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 257 | $247.22 | $63.5K | Form 4 |
| 2026-06-10 | Aryeh Jason | Director | Open-market sale | 500 | $250.00 | $125.0K | Form 4 |
| 2026-06-05 | Aryeh Jason | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | Aryeh Jason | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-05 | Gray Nancy Ryan | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | Gray Nancy Ryan | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-05 | Haas Jason | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | Haas Jason | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-05 | KOZARICH JOHN W | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | KOZARICH JOHN W | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-05 | LAMATTINA JOHN L | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | LAMATTINA JOHN L | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-05 | Sabba Stephen L | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | Sabba Stephen L | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-05 | Zimmermann Martine | Director | Grant / award / vesting (derivative) | 2,938 | — | $0 | Form 4 |
| 2026-06-05 | Zimmermann Martine | Director | Shares withheld for taxes / exercise cost | 182 | $237.00 | $43.1K | Form 4 |
| 2026-06-05 | Zimmermann Martine | Director | Grant / award / vesting | 836 | — | $0 | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 200 | $230.41 | $46.1K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,216 | $229.47 | $279.0K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 584 | $228.57 | $133.5K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 400 | $226.78 | $90.7K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,432 | $225.97 | $323.6K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 677 | $225.20 | $152.5K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 491 | $223.95 | $110.0K | Form 4 |
| 2026-06-01 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion | 5,000 | $52.27 | $261.4K | Form 4 |
| 2026-05-27 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 764 | — | $0 | Form 4 |
| 2026-05-27 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 972 | — | $0 | Form 4 |
| 2026-05-27 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 972 | $52.84 | $51.4K | Form 4 |
| 2026-05-27 | Espinoza Octavio | Officer (Chief Financial Officer) | Option exercise / conversion | 764 | $63.62 | $48.6K | Form 4 |
| 2026-05-13 | KOZARICH JOHN W | Director | Option exercise / conversion (derivative) | 1,575 | — | $0 | Form 4 |
| 2026-05-13 | KOZARICH JOHN W | Director | Open-market sale | 1,575 | $223.50 | $352.0K | Form 4 |
| 2026-05-13 | KOZARICH JOHN W | Director | Option exercise / conversion | 1,575 | $69.51 | $109.5K | Form 4 |
Ask the chat about LGND's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LIGAND PHARMACEUTICALS INC (LGND).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.